Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-012986
Filing Date
2025-05-15
Accepted
2025-05-15 09:39:46
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 43490
2 JOINT FILING AGREEMENT ex-99-05152025_010546.htm EX-99.1 12214
  Complete submission text file 0001415889-25-012986.txt   57750
Mailing Address 125 STRAFFORD AVE SUITE 360 WAYNE PA 19087
Business Address 125 STRAFFORD AVE SUITE 360 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Subject) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88917 | Film No.: 25949383
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A